Click it and Unblock the Notifications
NATCO Pharma has said that the US Court of Appeals for the Federal Circuit ruling, has reversed a district court's finding related to Teva's US Patent for Copaxone.
This would essentially mean that NATCO could launch the generic Copaxone - through its
marketing partner - Mylan Inc., during May 2014, subject to FDA approval. Copaxone (Glatiramer Acetate) is used in the treatment of relapsing-remitting multiple sclerosis.
The product is estimated to have clocked revenues, in USA, of about US $3.45 Billion during 2012.
Shares in Natco which closed at Rs 491 on Friday, may receive a boost when markets re-open for trading on Monday.
GoodReturns.in
More From GoodReturns
Gold Rates In India Today Crash Again On Inflation Fear; Gold Falls Rs36,500 In 3 Days; 24K, 22K, 18K Gold
Gold & Silver Rates Today Live: MCX Gold Crashes By Rs 5,645, Silver Falls By Rs 16,540; 24K, 22K, 18K Gold
1:5 Split Soon? Vedanta Ltd To Consider 3rd Interim Dividend On March 23, Share Jumps; Record Date & Buy Call
Gold Rates & Silver Rates Today Live: MCX Gold & Silver Price Gives Up Some Early Gains; 24K, 22K, 18K Gold
Gold Rates Crash by Rs. 33500/100g in 3 Days: Bangalore, Chennai, Hyderabad Record Sharp Fall on March 14
Bengaluru Power Cut Today: Key Areas To Face 7-Hour Power Outage for BESCOM Maintenance On March 15| Full List
Gold Rates In India Crash Continues Today, 24K, 22K, 18K Gold Prices On Mar-16; Gold Rate Falls By Rs 41,400
Emirates, Etihad, Air India Express Cancel Dubai, Abu Dhabi, Dammam Flights on 16-17 March; Check Status Today
DigiLocker PVR Storage: How Indian Citizens Can Digitally Save Passport Verification Records?
Massive Crash in Gold Rate in India! 24K Plunges Nearly Rs 59,000 in Four Sessions; Will Slide Continue Today?
New Income Tax Rules 2026: 8 Big Tax Changes Going Into Effect From 1 April
Sign in with Google